2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1240

Serum Anti-Müllerian Hormone Can Be Used to Determine Ovarian Reserve in Women with Rheumatoid Arthritis
Abstract Number: 1758

Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing After B Cell Depletion Therapy
Abstract Number: 2167

Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab
Abstract Number: 1623

Serum Biomarkers Signature Identifies Patients with Overt B-Cell Non-Hodgkin Lymphoma Associated with Mixed Cryoglobulinemia in Chronic HCV Infection
Abstract Number: 2124

Serum Concentrations of Soluble Interferon Receptor in Patients with Rheumatoid Arthritis
Abstract Number: 1269

Serum Cytokines Associated with Carotid Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 2260

Serum DNAse I Anti DNAse I Antibodies , CRP and Antibodies to CRP Relation to Disease Activity in Systemic Lupus Eryhtematous: Longitudinal Studies
Abstract Number: 1809

Serum IFNα Activity in Systemic Lupus Erythematosus Drops in Response to Immunosuppressive Therapy Only When There Is Concurrent Clinical Response
Abstract Number: 65

Serum Inflammatory Biomarkers Correlated Stronger with a Panel of Serum Steroid and Pituitary Hormones in a Cohort of Pre-Rheumatoid Arthritis (pre-RA) Than in Non-RA Control (CN) Subjects
Abstract Number: 2381

Serum Level of IL-33 and Soluble ST2 and Their Association with Disease Activity in Patients with Behcet’s Disease
Abstract Number: 613

Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 2280

Serum Metabolomics As a Novel Diagnostic Approach for Systemic Lupus Erythematosus
Abstract Number: 2248

Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) Identified As a Novel Biomarker for Systemic Lupus Erythematosus (SLE)
Abstract Number: 652

Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1916

Serum Uric Acid As a Biomarker for Mitigation of Infusion Reactions in Patients Treated with Pegloticase for Refractory Chronic Gout

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].